CRSP NASDAQ
CRISPR Therapeutics AG
1W: -1.1%
1M: -11.6%
3M: -6.7%
YTD: -7.2%
1Y: +27.1%
3Y: -19.1%
5Y: -53.2%
$50.36
+0.46 (+0.92%)
Weekly Expected Move ±9.2%
$40
$44
$48
$53
$57
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$4M
-90.0% ▼
5Y CAGR: +37.3%
Gross Profit
-$229M
-204.9% ▼
Operating Income
-$568M
-21.8% ▼
Net Income
-$582M
-58.8% ▼
EPS (Diluted)
$-6.47
-49.1% ▼
EBITDA
-$549M
-22.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $913M | $436K | $370M | $35M | $4M |
| YoY Growth | +168054.9% | -100.0% | +85039.0% | -90.6% | -90.0% |
| Cost of Revenue | $101M | $110M | $130M | $110M | $233M |
| Gross Profit | $812M | -$110M | $240M | -$75M | -$229M |
| Gross Margin | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| R&D Expenses | $341M | $462M | $387M | $321M | $265M |
| SG&A Expenses | $100M | $102M | $76M | $73M | $74M |
| Operating Expenses | $438M | $563M | $462M | $391M | $339M |
| Operating Income | $374M | -$673M | -$223M | -$467M | -$568M |
| Operating Margin | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | $380M | -$650M | -$151M | -$363M | -$578M |
| Tax Expense | $2M | -$325K | $3M | $4M | $4M |
| Net Income | $378M | -$650M | -$154M | -$366M | -$582M |
| Net Margin | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| EPS (Diluted) | $4.70 | $-8.36 | $-1.94 | $-4.34 | $-6.47 |
| EBITDA | $391M | -$649M | -$203M | -$447M | -$549M |
| Shares Outstanding | 80M | 78M | 79M | 84M | 90M |